Sign in
Taking people in South AfricaPhase 3

NXT007 versus usual clotting factor treatment for hemophilia A

Compares NXT007 with clotting factor preventive treatment in hemophilia A.

Key facts

Who runs it
Hoffmann-La Roche
Where
Parktown, South AfricaSee the siteAlso in 18 other countries, 42 sites
Registry title
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Status
Recruiting
Phase
Phase 3
People taking part
138 people, planned
Started
15 May 2026
Expected to end
23 Sept 2031
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NXT007
  • Human Coagulation Factor VIII
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 and older with severe or moderate congenital hemophilia A who have no FVIII inhibitors and are already on FVIII prophylaxis.

Age
12 years and older
Sex
All sexes can join.
Disease stage
Severe (FVIII:C <1 IU/dL) or moderate (FVIII:C between ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A without inhibitors against FVIII.
Earlier treatment
Must have been on FVIII prophylaxis before the study. Treatment details and bleeding episodes must be documented for at least the last 6 months before screening.
Biomarker or test result
No documented FVIII inhibitor (<0.6 BU/mL) in the last 3 years, and a negative inhibitor test within 12 months before enrollment. FVIII half-life ≥6 hours or FVIII recovery >66%.

Main reasons for not taking part

  • Allergy or sensitivity to the study treatments or their components
  • Use of systemic immunomodulators (for example interferon or rituximab) at enrollment or planned during the study, except anti-retroviral therapy for HIV
  • Planned surgery during the study (minor procedures excluded)
  • Clinically significant abnormal ECG, or prior heart attack
  • History of ventricular dysrhythmias or risk factors such as structural or coronary heart disease

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of severe (FVIII:C <1 IU/dL [International Unit per decilitre]) or moderate (FVIII:C between ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A without inhibitors against FVIII
  • No documented inhibitor (i.e., <0.6 BU/mL [Bethesda unit per millilitre]), FVIII half-life ≥6 hours, or FVIII recovery >66% in the last 3 years prior to screening
  • Documented historical negative test for FVIII inhibitor (i.e., <0.6 BU/mL) within 12 months prior to enrollment
  • Documentation of the details of prophylactic and episodic FVIII treatment and of the number and type of bleeding episodes for at least the last 6 months prior to screening
  • Agreement to adhere to the contraception requirements (for potential participants with childbearing potential)

Who cannot take part

  • Planned surgery (excluding minor procedures such as non-molar tooth extraction, incision and drainage) during the study
  • History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third- degree atrioventricular heart block) or ECG evidence or clinical history of prior myocardial infarction
  • Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
  • Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for anti-retroviral therapy to treat HIV
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)
  • Refusal to accept plasma-derived and/or blood product transfusion support in an emergency scenario

This trial is currently available in South Africa.

Also in 18 other countries, 42 sites

  • Haemophilia Comprehensive Care CentreParktown, South AfricaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without FVIII inhibitors. The study will include people aged ≥12 years old who have been on FVIII prophylaxis treatment prior to study entry.

The 3 groups in the trial

  • Main Study Treatment Period: NXT007 ProphylaxisTreatment being tested

    Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.

    Treatment: NXT007

  • Main Study Treatment Period: FVIII SOC ProphylaxisExisting treatment, for comparison

    Participants randomized to this arm will receive FVIII standard of care (SOC) prophylaxis for the main study treatment period.

    Treatment: Human Coagulation Factor VIII

  • Open-Label Extension Period: NXT007 ProphylaxisTreatment being tested

    After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the FVIII arm will be able to switch to NXT007, in the open-label extension period.

    Treatment: NXT007

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors
Plain-language title
NXT007 versus usual clotting factor treatment for hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 October 2026